Avadomide (CC-122) Clinical Trials

Size	Price	Qty
2mg	USD 147
5mg	USD 247

Clinical Trials

Numerous early-phase clinical trials—encompassing Phase 1, Phase 2, and combined Phase 1/2 studies—have evaluated avadomide (CC-122) across hematologic malignancies and solid tumors. Sponsored by pharmaceutical organizations and academic collaborators, these investigations examine single-agent safety, pharmacokinetics, and combination regimens in both patient populations and healthy volunteers. Trial recruitment statuses across this clinical portfolio include completed, active not recruiting, and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05688475	ACTIVE_NOT_RECRUITING	Non-Hodgkin Lymphoma	Bristol-Myers Squibb	2023-04-11	PHASE1
NCT02031419	TERMINATED	Lymphoma, Large B-Cell, Diffuse	Celgene	2013-12-18	PHASE1
NCT01421524	COMPLETED	Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Pleiotropic Pathway Modifier; Glioblastoma; Lymphoma; Primary Central Nervous System Lymphoma	Celgene	2011-09-12	PHASE1
NCT02509039	TERMINATED	Lymphoma, Non-Hodgkin	Celgene	2015-09-02	PHASE1
NCT05688475	Active not recruiting	Non-Hodgkin Lymphoma	Bristol-Myers Squibb	2023-04-11	Phase 1
NCT03310619	COMPLETED	Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular	Celgene	2017-12-20	PHASE1; PHASE2
NCT03834623	COMPLETED	Melanoma	H. Lee Moffitt Cancer Center and Research Institute	2019-05-14	PHASE2
NCT02406742	COMPLETED	Leukemia, Lymphocytic, Chronic, B-Cell	Celgene	2015-07-27	PHASE1; PHASE2
NCT02859324	COMPLETED	Carcinoma, Hepatocellular	Celgene	2016-09-20	PHASE1; PHASE2
NCT03283202	COMPLETED	Diffuse B-Cell Lymphoma	Celgene	2017-10-04	PHASE1
NCT02417285	COMPLETED	Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin	Celgene	2015-05-22	PHASE1
NCT03834623	Completed	Melanoma	H. Lee Moffitt Cancer Center and Research Institute\|Bristol-Myers Squibb\|Celgene Corporation	2019-05-14	Phase 2
NCT03340662	COMPLETED	Healthy Volunteer	Celgene	2017-11-09	PHASE1
NCT03097016	COMPLETED	Renal Insufficiency	Celgene	2017-03-30	PHASE1
NCT02323906	TERMINATED	Carcinoma, Hepatocellular	Celgene	2015-01-16	PHASE1
NCT02406742	Completed	Leukemia Lymphocytic Chronic B-Cell	Celgene	2015-07-27	Phase 1\|Phase 2
NCT02234999	COMPLETED	Healthy Volunteers	Celgene	2014-09-23	PHASE1
NCT02234999	Completed	Healthy Volunteers	Celgene	2014-09-23	Phase 1
NCT02049528	COMPLETED	Clinical Pharmacology, Healthy Male Volunteer Study	Celgene	2014-01-16	PHASE1
NCT01421524	Completed	Multiple Myeloma\|Lymphoma Large B-Cell Diffuse\|Pleiotropic Pathway Modifier\|Glioblastoma\|Lymphoma\|Primary Central Nervous System Lymphoma	Celgene	2011-09-12	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-05-11)

Check the Avadomide (CC-122) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Avadomide selectively binds to cereblon (CRBN), the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase complex, thereby promoting targeted ubiquitination and proteasomal degradation of substrate proteins to impair downstream oncogenic signaling pathways. This targeted protein degradation induces tumor cell apoptosis and enhances immunomodulatory cellular responses, providing antitumor activity in clinical trial settings such as diffuse large B-cell lymphoma, multiple myeloma, and advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).